Coya Therapeutics (NASDAQ: COYA) is a publicly traded clinical-stage biotechnology enterprise owned by a diverse mix of institutional asset management firms, mutual funds, corporate insiders, and retail public shareholders who hold its common stock on the Nasdaq exchange following its initial public offering.